Find clinical trials for Alzheimer's Disease in New York, NY
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Alzheimer's Disease trials near New York, NY, USA:
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Brooklyn, New York, United States of America and 67 other locations
clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild dementia due to Alzheimer's disease, an ...
Phase 1, Phase 2
New York, New York, United States and 3 other locations
the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's...
New York, New York, United States and 8 other locations
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...
Phase 3
Springfield, New Jersey, United States and 70 other locations
double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's...
Phase 2
Stamford, Connecticut, United States and 31 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
New York, New York, United States and 89 other locations
This is a pilot RCT with equal arms: experimental arm and (wait list) control arm.All participants will be in the early stage of Alzheimer's ...
New Brunswick, New Jersey, United States and 1 other location
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...
Phase 2, Phase 3
Bronx, New York, United States and 27 other locations
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
Phase 1, Phase 2
New York, New York, United States and 13 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
New York, New York, United States and 111 other locations
Clinical trials
Research sites
Resources
Legal